‘ENHANZE® drug delivery technology: Advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20’ provides readers with in-depth information on the potential benefits and challenges of subcutaneous (SC) drug delivery, the biology of hyaluronan and hyaluronidases in the SC space, and a comprehensive overview on the history of hyaluronidases and the development of recombinant human hyaluronidase PH20 (rHuPH20). Current applications of rHuPH20 as well as approved biotherapeutics utilizing HuPH20-facilitated SC drug delivery are summarized, and the underlying non-clinical and clinical development approaches are introduced as a basis for future application to biologics in various disease areas. Table of Contents: • Introduction to subcutaneous drug delivery • Biology of hyaluronan and hyaluronidases in the subcutaneous space • History of hyaluronidases and development of rHuPH20 • The ENHANZE® platform: Clinical applications of a subcutaneous drug delivery technology • Application of ENHANZE® drug delivery technology: Development of currently marketed products
